|1.||Klinowska, Teresa: 5 articles (08/2015 - 02/2010)|
|2.||Barlaam, Bernard: 2 articles (08/2013 - 02/2010)|
|3.||Vincent, John: 2 articles (08/2013 - 02/2010)|
|4.||Hickinson, D Mark: 2 articles (08/2013 - 02/2010)|
|5.||Anderton, Judith: 2 articles (08/2013 - 02/2010)|
|6.||Trigwell, Cath: 2 articles (08/2013 - 02/2010)|
|7.||Ogilvie, Donald: 2 articles (08/2013 - 02/2010)|
|8.||James, Neil H: 1 article (08/2015)|
|9.||Davies, Barry R: 1 article (08/2015)|
|10.||Tang, Eric: 1 article (08/2015)|
|1.||Breast Neoplasms (Breast Cancer)
08/01/2015 - "To determine whether inhibition of HER2 could increase the efficacy of AZD5363, a novel AKT inhibitor, a panel of breast cancer cells was dosed with AZD5363 in combination with AZD8931, an inhibitor of EGFR/HER2/HER3 signalling. "
08/01/2015 - "We conclude that the activity of AZD5363 in HER2-amplified breast cancer cells is enhanced by the addition of AZD8931 and that dual targeting of AKT and EGFR/HER2/HER3 signalling is an attractive treatment option to be explored in the clinic. "
08/01/2015 - "Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models."
10/01/2014 - "Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer."
04/01/2014 - "We therefore examined the effect of AZD8931 in ER-positive/HER2-negative breast cancer cells with acquired resistance to tamoxifen, where there is ligand up-regulation associated with HER pathway activation. "
02/01/2014 - "This Phase I, open-label study evaluated the safety, tolerability, and pharmacokinetics of multiple ascending doses of AZD8931 in patients with advanced solid tumors (NCT00637039). "
02/01/2014 - "Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors."
08/08/2013 - "AZD8931 is currently being evaluated in human clinical trials for the treatment of cancer. "
01/01/2014 - "These results suggest that AZD8931 may provide a novel therapeutic strategy for the treatment of IBC patients with HER2 non-amplified tumors."
08/08/2013 - "AZD8931 exhibited good pharmacokinetics in preclinical species and showed superior activity in the LoVo tumor growth efficacy model compared to close analogues. "
|3.||Inflammatory Breast Neoplasms
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||squamous cell of head and neck Carcinoma
|1.||Heterologous Transplantation (Xenotransplantation)